Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients

An increasing number of studies have shown altered expression of secreted protein acidic and rich in cysteine (SPARC) and N-myc down-regulated gene (NDRG1) in several malignancies, including breast carcinoma; however, the role of these potential biomarkers in tumor development and progression is controversial. In this study, NDRG1 and SPARC protein expression was evaluated by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with 10 years of follow-up. NDRG1 and SPARC protein expression was determined in 596 patients along with other prognostic markers, such as ER, PR, and HER2. The status of NDRG1 and SPARC protein expression was correlated with prognostic variables and patient clinical outcome. Immunostaining revealed that 272 of the 596 cases (45.6%) were positive for NDRG1 and 431 (72.3%) were positive for SPARC. Statistically significant differences were found between the presence of SPARC and NDRG1 protein expression and standard clinicopathological variables. Kaplan–Meier analysis showed that NDRG1 positivity was directly associated with shorter disease-free survival (DFS, P < 0.001) and overall survival (OS, P < 0.001). In contrast, patients expressing low levels of SPARC protein had worse DFS (P = 0.001) and OS (P = 0.001) compared to those expressing high levels. Combined analysis of the two markers indicated that DFS (P < 0.001) and OS rates (P < 0.001) were lowest for patients with NDRG1-positive and SPARC-negative tumors. Furthermore, NDRG1 over-expression and SPARC down-regulation correlated with poor prognosis in patients with luminal A or triple-negative subtype breast cancer. On multivariate analysis using a Cox proportional hazards model, NDRG1 and SPARC protein expression were independent prognostic factors for both DFS and OS of breast cancer patients. These data indicate that NDRG1 over-expression and SPARC down-regulation could play important roles in breast cancer progression and serve as useful biomarkers to better define breast cancer prognosis.

[1]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[2]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[3]  H. Ford,et al.  Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. , 2000, Cancer research.

[4]  W. Dinjens,et al.  A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[5]  Ken Saito,et al.  Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression , 2004, Oncogene.

[6]  C. Brodie,et al.  SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion , 2008, International journal of cancer.

[7]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[8]  J. Rosen,et al.  Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.

[9]  Hung-Ming Wang,et al.  Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): Overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1 , 2005, International journal of cancer.

[10]  M. Nagai,et al.  Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression. , 2006, International journal of oncology.

[11]  E. Thompson,et al.  Doxycycline-Inducible Expression of SPARC/ Osteonectin/ BM40 in MDA-MB-231 Human Breast Cancer Cells Results in Growth Inhibition , 2002, Breast Cancer Research and Treatment.

[12]  S. Sleijfer,et al.  Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response , 2008, Clinical Cancer Research.

[13]  D. Owen,et al.  SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response , 2008, British Journal of Cancer.

[14]  D. Ross,et al.  Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma , 2007, Modern Pathology.

[15]  Hakan Cangul,et al.  Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers , 2004, BMC Genetics.

[16]  D. Owen,et al.  Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. , 2005, The Journal of clinical investigation.

[17]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[18]  Ole N Jensen,et al.  Metastasis-related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.

[19]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[20]  W. Stolz,et al.  Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes , 2003, Experimental dermatology.

[21]  M. Yamaguchi,et al.  17β-Estradiol Induces Down-Regulation of Cap43/NDRG1/Drg-1, a Putative Differentiation-Related and Metastasis Suppressor Gene, in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  R. Berkowitz,et al.  SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. , 2001, The American journal of pathology.

[24]  L. Chung,et al.  Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. , 2007, Current problems in cancer.

[25]  M. Westfall,et al.  NDRG1 Is Necessary for p53-dependent Apoptosis* , 2004, Journal of Biological Chemistry.

[26]  T. Pawełczyk,et al.  Identification of High-Risk Stage II Colorectal Tumors by Combined Analysis of the NDRG1 Gene Expression and the Depth of Tumor Invasion , 2009, Annals of Surgical Oncology.

[27]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[28]  R. Moll,et al.  Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast , 2005, Virchows Archiv.

[29]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[30]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[31]  Rolf A. Brekken,et al.  SPARC: a matricellular regulator of tumorigenesis , 2009, Journal of Cell Communication and Signaling.

[32]  D. Polsky,et al.  Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients , 2004, Clinical Cancer Research.

[33]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[34]  G. Watkins,et al.  Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[35]  S. Mok,et al.  Aberrant promoter methylation of SPARC in ovarian cancer. , 2009, Neoplasia.

[36]  T. Mikkelsen,et al.  SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. , 1998, Journal of neuropathology and experimental neurology.

[37]  C. Caldas,et al.  Triple negative breast cancers: clinical and prognostic implications. , 2009, European journal of cancer.

[38]  M. Herlyn,et al.  Unraveling mysteries of the multifunctional protein SPARC. , 2007, The Journal of investigative dermatology.

[39]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[40]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[41]  Qiwei Yang,et al.  SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix , 2006, International journal of cancer.

[42]  R. Hynes,et al.  Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer , 2007, Clinical & Experimental Metastasis.

[43]  A. Norton,et al.  Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.

[44]  E Helene Sage,et al.  Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. , 2004, Molecular cancer research : MCR.

[45]  Andrew H. Beck,et al.  The fibromatosis signature defines a robust stromal response in breast carcinoma , 2008, Laboratory Investigation.

[46]  N. Sneige,et al.  The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  M. Kuwano,et al.  Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. , 2006, Cancer research.

[48]  F. Bosman,et al.  Expression of NDRG1, a differentiation-related gene, in human tissues , 2002, Histochemistry and Cell Biology.

[49]  Alan Mackay,et al.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.